Healthcare -
Biotechnology - NYSE - US
$ 1.8
8.43 %
$ 608 M
Market Cap
-0.85
P/E
1. INTRINSIC VALUE
Balance Sheet
Nuvation Bio Inc.
| Current Assets | 526 M |
| Cash & Short-Term Investments | 503 M |
| Receivables | 16.3 M |
| Other Current Assets | 7.27 M |
| Non-Current Assets | 14.4 M |
| Long-Term Investments | 0 |
| PP&E | 2.99 M |
| Other Non-Current Assets | 11.4 M |
| Current Liabilities | 58.2 M |
| Accounts Payable | 6.35 M |
| Short-Term Debt | 7.95 M |
| Other Current Liabilities | 44 M |
| Non-Current Liabilities | 18.6 M |
| Long-Term Debt | 969 K |
| Other Non-Current Liabilities | 17.6 M |
EFFICIENCY
Earnings Waterfall
Nuvation Bio Inc.
| Revenue | 7.87 M |
| Cost Of Revenue | 7.08 M |
| Gross Profit | 795 K |
| Operating Expenses | 593 M |
| Operating Income | -593 M |
| Other Expenses | -24.7 M |
| Net Income | -568 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nuvation Bio Inc.
| Net Income | -568 M |
| Depreciation & Amortization | 683 K |
| Capital Expenditures | -162 K |
| Stock-Based Compensation | 32.3 M |
| Change in Working Capital | 0 |
| Others | 405 M |
| Free Cash Flow | -131 M |
Wall Street Analysts Price Targets
Nuvation Bio Inc.
Wall Street analysts predict an average 1-year price target for NUVB of $6.71 , with forecasts ranging from
a
low of
$5 to a high of $10 .
NUVB Lowest Price Target
Wall Street Target
5 USD
177.78%
NUVB Average Price Target
Wall Street Target
6.71 USD
273.02%
NUVB Highest Price Target
Wall Street Target
10 USD
455.56%
4. DIVIDEND
ANALYSIS
NUVB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Nuvation Bio Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
163 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
167 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
220 K USD 1
6-9 MONTHS
2.82 M USD 2
9-12 MONTHS
7. News
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 10:00 a.m. PT/1:00 p.m. ET in Las Vegas, NV. An audio.
businesswire.com
- 1 week ago
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois. Presentation Overview: Title: Taletrectinib, a next generation selective ROS1 inhibitor,.
businesswire.com
- 2 weeks ago
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France. Mini Oral Presentation Overview: Ti.
businesswire.com
- 2 weeks ago
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “Nuvation Bio had a transformative year in 2024, marked by significant milestones. We acquired AnHeart Therapeutics, reported positive pivotal data for taletrectinib, and submitted the NDA for taletrectinib, which was accep.
businesswire.com
- 1 month ago
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners (Sagard). The transaction comprises a royalty interest financing of $150 million and a senior term loan of up to $100 million. These financings strengthen Nuvation Bio's balance sheet to fully fund commercialization of taletrectinib in the U.S., if approve.
businesswire.com
- 1 month ago
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investo.
businesswire.com
- 1 month ago
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
prnewswire.com
- 1 month ago
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism.
seekingalpha.com
- 1 month ago
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no comparable or satisfactory alternative therapy options are available. “This EAP reflects our unwavering dedication to patie.
businesswire.com
- 2 months ago
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT in San Francisco, California. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuv.
businesswire.com
- 3 months ago
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China , Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The approval is based on positive results from the pivotal Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated the safety, tolerability and efficiency of taletrectinib in Chinese patients with advanced ROS1-positive NSCLC.
prnewswire.com
- 3 months ago
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company's NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2.
businesswire.com
- 3 months ago
8. Profile
Summary
Nuvation Bio Inc. NUVB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 608 M
Dividend Yield
0.00%
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Contact
1500 Broadway, New York, NY, 10036
https://www.nuvationbio.com
IPO
Date
Aug. 26, 2020
Employees
220
Officers
Dr. David T. Hung M.D.
Founder, President, Chief Executive Officer & Chairman
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Ms. Colleen Sjogren
Chief Commercial Officer
Dr. Gary Hattersley Ph.D.
Chief Scientific Officer
Dr. David Liu M.D., Ph.D.
Chief Medical Officer
Stephen Dang
Vice President of Legal & Secretary
Mr. Philippe Sauvage
Chief Financial Officer & Principal Financial Officer
Ms. Stacy Markel
Chief People Officer
Dr. David C. Hanley Ph.D.
Chief Technical Operations Officer
Mr. Moses Makunje CPA
Vice President of Finance and Principal Accounting & Financial Officer